With a year full of read­outs ahead, Disc Med­i­cine se­cures cash from Bain Cap­i­tal

Disc Med­i­cine has sold shares to raise $62.5 mil­lion in a di­rect of­fer­ing, it an­nounced Tues­day morn­ing.

Of that fi­nanc­ing, $50 mil­lion came from new in­vestor Bain Cap­i­tal, fol­lowed by ex­ist­ing in­vestors Ac­cess Biotech­nol­o­gy and Or­biMed.

The Wa­ter­town, MA biotech went pub­lic at the end of last year via a re­verse merg­er with Gem­i­ni Ther­a­peu­tics, adopt­ing the tick­er $IRON to re­flect its role as a blood dis­or­ders biotech. Pres­i­dent and CEO John Quisel told End­points News that Disc de­cid­ed to go pub­lic since it has a num­ber of im­por­tant da­ta read­outs this year. “With that comes both the op­por­tu­ni­ty to rec­og­nize val­ue in­creas­es in the com­pa­ny, but al­so the need for cap­i­tal as we ad­vance deep­er in­to the clin­ic,” he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER